Physician profile
Alan Moylan
NPI 1669904330
$2,960.42
in general payments reported to CMS, 2019-2025
22 companies · $429 in 2025
The $429 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $505 · 2022: $621 · 2023: $630 · 2024: $667 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $656.11 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $624.90 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $257.80 | 2020-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $255.94 | 2020-2022 | |
| Sobi, INC | $234.33 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $140.48 | 2021-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Sanofi Pasteur INC. | $124.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $98.57 | 2023-2025 | Bexsero, Pediarix, Rotarix |
| Adlon Therapeutics L.P. | $87.74 | 2021 | |
| Neos Therapeutics, Lp | $77.98 | 2021-2022 | |
| Kaleo, INC. | $64.93 | 2022-2023 | Auvi-Q |
| Biomarin Pharmaceutical INC. | $54.00 | 2025 | Voxzogo 1.2mg |
| Azurity Pharmaceuticals, INC. | $51.72 | 2025 | Alvesco |
| Tris Pharma INC | $50.68 | 2022-2023 | Dyanavel Xr |
| Pfizer INC. | $43.11 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $31.30 | 2025 | Jornay Pm |
| Neurelis, INC. | $29.59 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $15.90 | 2025 | Relexxii |
| Verrica Pharmaceuticals INC. | $15.46 | 2025 | Ycanth |
| Noven Therapeutics, LLC | $14.56 | 2025 | Xelstrym |
| Alk-Abello, INC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Moylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.